Investors appear to be excited by the prospect of the new "right-to-try" legislation that President Trump signed into law on May 30, 2018. In brief, this newly minted law allows terminally ill patients to access experimental treatments like those being developed by Ziopharm.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,